The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.
Allogene Therapeutics has announced an expanded collaboration with Foresight Diagnostics to develop a minimal residual disease (MRD) assay as a companion diagnostic tool for identifying patients with ...
Persistent outcome disparities, particularly worse prognoses for Black women with breast cancer, persist even within the same genomic risk categories. Effective management requires integrating genomic ...
The Stagljar Lab is a global leader in proteomics and chemical genomics, specializing in unraveling protein-protein interactions of human membrane proteins. Pivotal in cancer and rare genetic diseases ...
Please provide your email address to receive an email when new articles are posted on . The CNSide assay aims to help clinicians with early diagnosis, treatment plans for those with CNS cancers. The ...
Published in JCO Precision Oncology, the new analytical validation standards offer an industry-wide protocol for test developersCHICAGO, Jan. 15, 2026 /PRNewswire/ -- A new consensus document ...
Understanding Interactions Leads to Better Assays as well as Time and Cost Savings Thorough elucidation of biomolecular interactions is central to understanding biology and disease mechanisms and ...
MENLO PARK, Calif., Nov. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been ...
DELRAY BEACH, Fla.--(BUSINESS WIRE)--PanGIA Biotech–a pioneer in liquid biopsy technology–today announced its first international partnership, collaborating with Canary Oncoceutics (Canary Oncoceutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results